UBS Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-21,031
| Closed | -$38.9K | – | 10343 |
|
|
2023
Q1 | $38.9K | Buy |
21,031
+9,204
| +78% | +$11.4K | ﹤0.01% | 6619 |
|
|
2022
Q4 | $13.1K | Buy |
11,827
+11,596
| +5,020% | +$16.5K | ﹤0.01% | 8195 |
|
|
2022
Q3 | $1K | Sell |
231
-26,556
| -99% | -$94K | ﹤0.01% | 10189 |
|
|
2022
Q2 | $82K | Buy |
26,787
+14,200
| +113% | +$69.1K | ﹤0.01% | 5574 |
|
|
2022
Q1 | $85K | Sell |
12,587
-10,490
| -45% | -$74.8K | ﹤0.01% | 6040 |
|
|
2021
Q4 | $193K | Buy |
23,077
+11,753
| +104% | +$96.8K | ﹤0.01% | 5739 |
|
|
2021
Q3 | $84K | Sell |
11,324
-6,997
| -38% | -$43.3K | ﹤0.01% | 5951 |
|
|
2021
Q2 | $125K | Sell |
18,321
-1,062
| -5% | -$8.82K | ﹤0.01% | 5713 |
|
|
2021
Q1 | $199K | Buy |
19,383
+15,280
| +372% | +$167K | ﹤0.01% | 5493 |
|
|
2020
Q4 | $29K | Buy |
4,103
+3,334
| +434% | +$25.9K | ﹤0.01% | 6672 |
|
|
2020
Q3 | $6K | Sell |
769
-4,691
| -86% | -$29.1K | ﹤0.01% | 7259 |
|
|
2020
Q2 | $38K | Sell |
5,460
-9,142
| -63% | -$49.3K | ﹤0.01% | 6108 |
|
|
2020
Q1 | $69K | Sell |
14,602
-5,793
| -28% | -$33.3K | ﹤0.01% | 5578 |
|
|
2019
Q4 | $178K | Buy |
20,395
+7,915
| +63% | +$42.8K | ﹤0.01% | 5676 |
|
|
2019
Q3 | $41K | Buy |
12,480
+9,549
| +326% | +$38.2K | ﹤0.01% | 6314 |
|
|
2019
Q2 | $15K | Buy |
2,931
+628
| +27% | +$3.33K | ﹤0.01% | 6825 |
|
|
2019
Q1 | $14K | Sell |
2,303
-4,399
| -66% | -$21.3K | ﹤0.01% | 6610 |
|
|
2018
Q4 | $22K | Buy |
6,702
+2,461
| +58% | +$11.5K | ﹤0.01% | 6720 |
|
|
2018
Q3 | $28K | Buy |
4,241
+3,991
| +1,596% | +$29.7K | ﹤0.01% | 6599 |
|
|
2018
Q2 | $2K | Sell |
250
-1,081
| -81% | -$15.6K | ﹤0.01% | 7755 |
|
|
2018
Q1 | $30K | Buy |
1,331
+17
| +1% | +$377 | ﹤0.01% | 6092 |
|
|
2017
Q4 | $17K | Buy |
1,314
+950
| +261% | +$14K | ﹤0.01% | 6690 |
|
|
2017
Q3 | $6K | Buy |
+364
| New | +$5.15K | ﹤0.01% | 7170 |
|
|
2017
Q2 | – | Sell |
-1,110
| Closed | -$24K | – | 8092 |
|
|
2017
Q1 | $24K | Buy |
+1,110
| New | +$23.5K | ﹤0.01% | 6026 |
|
Other funds holding JNCE
UBS Group's JNCE Position: Q2 2023 in Review
UBS Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 21,031 shares — an estimated $38.9K sold.
UBS Group first reported a position in JNCE in Q1 2017 and held it in 24 quarters. The position peaked at $199K in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- UBS Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 21,031 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $38.9K.
- UBS Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 24 quarters.
- UBS Group's Jounce Therapeutics, Inc. Common Stock position peaked at $199K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.